nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

21.10.2023 | Original Article

Exploring the association of glioma tumor residuals from incongruent [¹⁸F]FET PET/MR imaging with tumor proliferation using a multiparametric MRI radiomics nomogram

verfasst von: Xiaoran Li, Ye Cheng, Xin Han, Bixiao Cui, Jing Li, Hongwei Yang, Geng Xu, Qingtang Lin, Xinru Xiao, Jie Tang, Jie Lu

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 3/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The study aimed to using multiparametric MRI radiomics to predict glioma tumor residuals (TR_{FET over MR}) derived from incongruent [¹⁸F]fluoroethyl-L-tyrosine ([¹⁸F]FET) PET/MR imaging.

Methods

One hundred ten patients with gliomas who underwent [¹⁸F]FET PET/MR scanning were retrospectively analyzed. The TR_{FET over MR} was identified by the discrepancy-PET that the extent of resection (EOR) based on MRI subtracted the biological tumor volume on PET images. The MRI parameters and radiomics features were extracted based on EOR and selected by the least absolute shrinkage and selection operator to construct radiomics score (Rad-score). The correlation network analysis of all features was analyzed by Spearman’s correlation tests. The methods for evaluating the clinical usefulness consisted of the receiver operating characteristic curve, the calibration curve, and decision curve analysis.

Results

The Rad-score of the patients with the TR_{FET over MR} was significantly higher than those with the non TR_{FET over MR} (p < 0.001). The Rad-score was significantly correlated with the discrepancy-PET (r = 0.72, p < 0.001), Ki-67 level (r = 0.76, p < 0.001), and epidermal growth factor receptor (EGFR) of gliomas (r = 0.75, p < 0.001), respectively. Moreover, there was a difference of the correlation network analysis between the TR_{PET over MR} group and non TR_{FET over MR} group. The nomogram combing Rad-score and clinical features had the greatest performance in predicting TR_{FET over MR} (AUC = 0.90/0.87, training/testing). There was a significant difference in prognosis (median OS, 17 m vs. 43 m) between patients with TR_{FET over MR} and non TR_{FET over MR} based on nomogram prediction (p < 0.001).

Conclusion

The nomogram based on MRI radiomics would predict gliomas tumor residuals caused by the absence of ¹⁸F-PET PET examination and adjust EOR to improve prognosis.

Nur mit Berechtigung zugänglich

Patel AP, Fisher JL, Nichols E, Abd-Allah F, Abdela J, Abdelalim A, et al. Global, regional, and national burden of brain and other CNS cancer, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:376–93. https://doi.org/10.1016/s1474-4422(18)30468-x.CrossRef

Miller KD, Ostrom QT, Kruchko C, Patil N, Tihan T, Cioffi G, et al. Brain and other central nervous system tumor statistics, 2021. CA Cancer J Clin. 2021;71:381–406. https://doi.org/10.3322/caac.21693.CrossRefPubMed

Redjal N, Venteicher AS, Dang D, Sloan A, Kessler RA, Baron RR, et al. Guidelines in the management of CNS tumors. J Neurooncol. 2021;151:345–59. https://doi.org/10.1007/s11060-020-03530-8.CrossRefPubMed

Ruda R, Capper D, Waldman AD, Pallud J, Minniti G, Kaley TJ, et al. EANO - EURACAN - SNO Guidelines on circumscribed astrocytic gliomas, glioneuronal, and neuronal tumors. Neuro Oncol. 2022;24:2015–34. https://doi.org/10.1093/neuonc/noac188.CrossRefPubMedPubMedCentral

Ostrom QT, Cote DJ, Ascha M, Kruchko C, Barnholtz-Sloan JS. Adult glioma incidence and survival by race or ethnicity in the United States from 2000 to 2014. JAMA Oncol. 2018;4:1254–62. https://doi.org/10.1001/jamaoncol.2018.1789.CrossRefPubMedPubMedCentral

Xu DS, Awad AW, Mehalechko C, Wilson JR, Ashby LS, Coons SW, et al. An extent of resection threshold for seizure freedom in patients with low-grade gliomas. J Neurosurg. 2018;128:1084–90. https://doi.org/10.3171/2016.12.JNS161682.CrossRefPubMed

Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001;95:190–8. https://doi.org/10.3171/jns.2001.95.2.0190.CrossRefPubMed

Ellingson BM, Wen PY, Cloughesy TF. Evidence and context of use for contrast enhancement as a surrogate of disease burden and treatment response in malignant glioma. Neuro Oncol. 2018;20:457–71. https://doi.org/10.1093/neuonc/nox193.CrossRefPubMed

Kim YZ, Kim CY, Lim DH. The overview of practical guidelines for gliomas by KSNO, NCCN, and EANO. Brain Tumor Res Treat. 2022;10:83–93. https://doi.org/10.14791/btrt.2022.0001.CrossRefPubMedPubMedCentral

10.

Verger A, Filss CP, Lohmann P, Stoffels G, Sabel M, Wittsack HJ, et al. Comparison of (18)F-FET PET and perfusion-weighted MRI for glioma grading: a hybrid PET/MR study. Eur J Nucl Med Mol Imaging. 2017;44:2257–65. https://doi.org/10.1007/s00259-017-3812-3.CrossRefPubMed

11.

Lohmann P, Stavrinou P, Lipke K, Bauer EK, Ceccon G, Werner JM, et al. FET PET reveals considerable spatial differences in tumour burden compared to conventional MRI in newly diagnosed glioblastoma. Eur J Nucl Med Mol Imaging. 2019;46:591–602. https://doi.org/10.1007/s00259-018-4188-8.CrossRefPubMed

12.

Verburg N, Koopman T, Yaqub MM, Hoekstra OS, Lammertsma AA, Barkhof F, et al. Improved detection of diffuse glioma infiltration with imaging combinations: a diagnostic accuracy study. Neuro Oncol. 2020;22:412–22. https://doi.org/10.1093/neuonc/noz180.CrossRefPubMed

13.

Song S, Cheng Y, Ma J, Wang L, Dong C, Wei Y, et al. Simultaneous FET-PET and contrast-enhanced MRI based on hybrid PET/MR improves delineation of tumor spatial biodistribution in gliomas: a biopsy validation study. Eur J Nucl Med Mol Imaging. 2020;47:1458–67. https://doi.org/10.1007/s00259-019-04656-2.CrossRefPubMedPubMedCentral

14.

Filss CP, Galldiks N, Stoffels G, Sabel M, Wittsack HJ, Turowski B, et al. Comparison of 18F-FET PET and perfusion-weighted MR imaging: a PET/MR imaging hybrid study in patients with brain tumors. J Nucl Med. 2014;55:540–5. https://doi.org/10.2967/jnumed.113.129007.CrossRefPubMed

15.

Henriksen OM, Larsen VA, Muhic A, Hansen AE, Larsson HBW, Poulsen HS, et al. Simultaneous evaluation of brain tumour metabolism, structure and blood volume using [(18)F]-fluoroethyltyrosine (FET) PET/MRI: feasibility, agreement and initial experience. Eur J Nucl Med Mol Imaging. 2016;43:103–12. https://doi.org/10.1007/s00259-015-3183-6.CrossRefPubMed

16.

Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2021;18:170–86. https://doi.org/10.1038/s41571-020-00447-z.CrossRefPubMed

17.

Ort J, Hamou HA, Kernbach JM, Hakvoort K, Blume C, Lohmann P, et al. (18)F-FET-PET-guided gross total resection improves overall survival in patients with WHO grade III/IV glioma: moving towards a multimodal imaging-guided resection. J Neurooncol. 2021;155:71–80. https://doi.org/10.1007/s11060-021-03844-1.CrossRefPubMedPubMedCentral

18.

Stockhammer F, Plotkin M, Amthauer H, van Landeghem FK, Woiciechowsky C. Correlation of F-18-fluoro-ethyl-tyrosin uptake with vascular and cell density in non-contrast-enhancing gliomas. J Neurooncol. 2008;88:205–10. https://doi.org/10.1007/s11060-008-9551-3.CrossRefPubMed

19.

Garcia Vicente AM, Perez-Beteta J, Amo-Salas M, Pena Pardo FJ, Villena Martin M, Sandoval Valencia H, et al. 18F-Fluorocholine PET/CT in the prediction of molecular subtypes and prognosis for gliomas. Clin Nucl Med. 2019;44:e548–58. https://doi.org/10.1097/RLU.0000000000002715.CrossRefPubMed

20.

Artzi M, Liberman G, Blumenthal DT, Aizenstein O, Bokstein F, Ben BD. Differentiation between vasogenic edema and infiltrative tumor in patients with high-grade gliomas using texture patch-based analysis. J Magn Reson Imaging. 2018. https://doi.org/10.1002/jmri.25939.CrossRefPubMed

21.

Dasgupta A, Geraghty B, Maralani PJ, Malik N, Sandhu M, Detsky J, et al. Quantitative mapping of individual voxels in the peritumoral region of IDH-wildtype glioblastoma to distinguish between tumor infiltration and edema. J Neurooncol. 2021;153:251–61. https://doi.org/10.1007/s11060-021-03762-2.CrossRefPubMed

22.

Zhang J, Yao K, Liu P, Liu Z, Han T, Zhao Z, et al. A radiomics model for preoperative prediction of brain invasion in meningioma non-invasively based on MRI: a multicentre study. EBioMedicine. 2020;58: 102933. https://doi.org/10.1016/j.ebiom.2020.102933.CrossRefPubMedPubMedCentral

23.

Bobholz SA, Lowman AK, Barrington A, Brehler M, McGarry S, Cochran EJ, et al. Radiomic features of multiparametric MRI present stable associations with analogous histological features in patients with brain cancer. Tomography. 2020;6:160–9. https://doi.org/10.18383/j.tom.2019.00029.CrossRefPubMedPubMedCentral

24.

Gihr G, Horvath-Rizea D, Kohlhof-Meinecke P, Ganslandt O, Henkes H, Hartig W, et al. Diffusion weighted imaging in gliomas: a histogram-based approach for tumor characterization. Cancers (Basel). 2022;14. https://doi.org/10.3390/cancers14143393.

25.

Li Y, Qian Z, Xu K, Wang K, Fan X, Li S, et al. Radiomic features predict Ki-67 expression level and survival in lower grade gliomas. J Neurooncol. 2017;135:317–24. https://doi.org/10.1007/s11060-017-2576-8.CrossRefPubMed

26.

Li Y, Liu X, Xu K, Qian Z, Wang K, Fan X, et al. MRI features can predict EGFR expression in lower grade gliomas: a voxel-based radiomic analysis. Eur Radiol. 2018;28:356–62. https://doi.org/10.1007/s00330-017-4964-z.CrossRefPubMed

27.

Yoo RE, Choi SH, Cho HR, Kim TM, Lee SH, Park CK, et al. Tumor blood flow from arterial spin labeling perfusion MRI: a key parameter in distinguishing high-grade gliomas from primary cerebral lymphomas, and in predicting genetic biomarkers in high-grade gliomas. J Magn Reson Imaging. 2013;38:852–60. https://doi.org/10.1002/jmri.24026.CrossRefPubMed

28.

Law I, Albert NL, Arbizu J, Boellaard R, Drzezga A, Galldiks N, et al. Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [(18)F]FDG: version 1.0. Eur J Nucl Med Mol Imaging. 2019;46:540–57. https://doi.org/10.1007/s00259-018-4207-9.

29.

Spangler-Bickell MG, Khalighi MM, Hoo C, DiGiacomo PS, Maclaren J, Aksoy M, et al. Rigid motion correction for brain PET/MR imaging using optical tracking. IEEE Trans Radiat Plasma Med Sci. 2019;3:498–503. https://doi.org/10.1109/TRPMS.2018.2878978.CrossRefPubMed

30.

Wang J, Zheng X, Zhang J, Xue H, Wang L, Jing R, et al. An MRI-based radiomics signature as a pretreatment noninvasive predictor of overall survival and chemotherapeutic benefits in lower-grade gliomas. Eur Radiol. 2021;31:1785–94. https://doi.org/10.1007/s00330-020-07581-3.CrossRefPubMed

31.

Varlet P, Le Teuff G, Le Deley MC, Giangaspero F, Haberler C, Jacques TS, et al. WHO grade has no prognostic value in the pediatric high-grade glioma included in the HERBY trial. Neuro Oncol. 2020;22:116–27. https://doi.org/10.1093/neuonc/noz142.CrossRefPubMed

32.

Menze BH, Jakab A, Bauer S, Kalpathy-Cramer J, Farahani K, Kirby J, et al. The multimodal brain tumor image segmentation benchmark (BRATS). IEEE Trans Med Imaging. 2015;34:1993–2024. https://doi.org/10.1109/TMI.2014.2377694.CrossRefPubMed

33.

Almeida JP, Chaichana KL, Rincon-Torroella J, Quinones-Hinojosa A. The value of extent of resection of glioblastomas: clinical evidence and current approach. Curr Neurol Neurosci Rep. 2015;15:517. https://doi.org/10.1007/s11910-014-0517-x.CrossRefPubMed

34.

Hua T, Zhou W, Zhou Z, Guan Y, Li M. Heterogeneous parameters based on (18)F-FET PET imaging can non-invasively predict tumor grade and isocitrate dehydrogenase gene 1 mutation in untreated gliomas. Quant Imaging Med Surg. 2021;11:317–27. https://doi.org/10.21037/qims-20-723.CrossRefPubMedPubMedCentral

35.

van Griethuysen JJM, Fedorov A, Parmar C, Hosny A, Aucoin N, Narayan V, et al. Computational radiomics system to decode the radiographic phenotype. Cancer Res. 2017;77:e104–7. https://doi.org/10.1158/0008-5472.CAN-17-0339.CrossRefPubMedPubMedCentral

36.

Shiri I, Hajianfar G, Sohrabi A, Abdollahi H, S PS, Geramifar P, et al. Repeatability of radiomic features in magnetic resonance imaging of glioblastoma: test-retest and image registration analyses. Med Phys. 2020;47:4265–80. https://doi.org/10.1002/mp.14368.

37.

Li G, Li L, Li Y, Qian Z, Wu F, He Y, et al. An MRI radiomics approach to predict survival and tumour-infiltrating macrophages in gliomas. Brain. 2022;145:1151–61. https://doi.org/10.1093/brain/awab340.CrossRefPubMedPubMedCentral

38.

Hu X, Sun X, Hu F, Liu F, Ruan W, Wu T, et al. Multivariate radiomics models based on (18)F-FDG hybrid PET/MRI for distinguishing between Parkinson’s disease and multiple system atrophy. Eur J Nucl Med Mol Imaging. 2021;48:3469–81. https://doi.org/10.1007/s00259-021-05325-z.CrossRefPubMed

39.

John F, Bosnyak E, Robinette NL, Amit-Yousif AJ, Barger GR, Shah KD, et al. Multimodal imaging-defined subregions in newly diagnosed glioblastoma: impact on overall survival. Neuro Oncol. 2019;21:264–73. https://doi.org/10.1093/neuonc/noy169.CrossRefPubMed

40.

Gottler J, Lukas M, Kluge A, Kaczmarz S, Gempt J, Ringel F, et al. Intra-lesional spatial correlation of static and dynamic FET-PET parameters with MRI-based cerebral blood volume in patients with untreated glioma. Eur J Nucl Med Mol Imaging. 2017;44:392–7. https://doi.org/10.1007/s00259-016-3585-0.CrossRefPubMed

41.

Wyss MT, Hofer S, Hefti M, Bartschi E, Uhlmann C, Treyer V, et al. Spatial heterogeneity of low-grade gliomas at the capillary level: a PET study on tumor blood flow and amino acid uptake. J Nucl Med. 2007;48:1047–52. https://doi.org/10.2967/jnumed.106.038489.CrossRefPubMed

42.

Juhasz C, Chugani DC, Barger GR, Kupsky WJ, Chakraborty PK, Muzik O, et al. Quantitative PET imaging of tryptophan accumulation in gliomas and remote cortex: correlation with tumor proliferative activity. Clin Nucl Med. 2012;37:838–42. https://doi.org/10.1097/RLU.0b013e318251e458.CrossRefPubMedPubMedCentral

43.

Zhang L, Liu X, Xu X, Liu W, Jia Y, Chen W, et al. An integrative non-invasive malignant brain tumors classification and Ki-67 labeling index prediction pipeline with radiomics approach. Eur J Radiol. 2023;158: 110639. https://doi.org/10.1016/j.ejrad.2022.110639.CrossRefPubMed

44.

Wei RL, Wei XT. Advanced diagnosis of glioma by using emerging magnetic resonance sequences. Front Oncol. 2021;11: 694498. https://doi.org/10.3389/fonc.2021.694498.CrossRefPubMedPubMedCentral

45.

Su C, Jiang J, Zhang S, Shi J, Xu K, Shen N, et al. Radiomics based on multicontrast MRI can precisely differentiate among glioma subtypes and predict tumour-proliferative behaviour. Eur Radiol. 2019;29:1986–96. https://doi.org/10.1007/s00330-018-5704-8.CrossRefPubMed

46.

Guo J, Ren J, Shen J, Cheng R, He Y. Do the combination of multiparametric MRI-based radiomics and selected blood inflammatory markers predict the grade and proliferation in glioma patients? Diagn Interv Radiol. 2021;27:440–9. https://doi.org/10.5152/dir.2021.20154.CrossRefPubMedPubMedCentral

47.

Zeng Q, Jiang B, Shi F, Ling C, Dong F, Zhang J. 3D Pseudocontinuous Arterial Spin-Labeling MR Imaging in the preoperative evaluation of gliomas. AJNR Am J Neuroradiol. 2017;38:1876–83. https://doi.org/10.3174/ajnr.A5299.CrossRefPubMedPubMedCentral

48.

Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19:1423–37. https://doi.org/10.1038/nm.3394.CrossRefPubMedPubMedCentral

49.

Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev Neurosci. 2007;8:610–22. https://doi.org/10.1038/nrn2175.CrossRefPubMed

50.

An Z, Aksoy O, Zheng T, Fan QW, Weiss WA. Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene. 2018;37:1561–75. https://doi.org/10.1038/s41388-017-0045-7.CrossRefPubMedPubMedCentral

51.

Schuster J, Lai RK, Recht LD, Reardon DA, Paleologos NA, Groves MD, et al. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. Neuro Oncol. 2015;17:854–61. https://doi.org/10.1093/neuonc/nou348.CrossRefPubMedPubMedCentral

Titel: Exploring the association of glioma tumor residuals from incongruent [18F]FET PET/MR imaging with tumor proliferation using a multiparametric MRI radiomics nomogram
verfasst von: Xiaoran Li
Ye Cheng
Xin Han
Bixiao Cui
Jing Li
Hongwei Yang
Geng Xu
Qingtang Lin
Xinru Xiao
Jie Tang
Jie Lu
Publikationsdatum: 21.10.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 3/2024
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-023-06468-x

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Exploring the association of glioma tumor residuals from incongruent [¹⁸F]FET PET/MR imaging with tumor proliferation using a multiparametric MRI radiomics nomogram

Abstract

Purpose

Methods

Results

Conclusion

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2024

Brain perfusion estimation by Tikhonov model-free deconvolution in a long axial field of view PET/CT scanner exploring five different PET tracers

Change in total lesion PSMA (TLP) during [177Lu]Lu-PSMA-617 radioligand therapy predicts overall survival in patients with mCRPC: monocentric evaluation of a prospective registry

Mono- and multimeric PSMA-targeting small molecule-thorium-227 conjugates for optimized efficacy and biodistribution in preclinical models

Development of a novel 18F-labeled small molecule probe for PET imaging of mesenchymal epithelial transition receptor expression

Epithelioid granuloma mimicking lung cancer showed intense uptake on [18F]FAPI-74 PET

The cycle effect quantified: reduced tumour uptake in subsequent cycles of [177Lu]Lu-HA-DOTATATE during peptide receptor radionuclide therapy